GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shan Dong Kexing Bioproducts Co Ltd (SHSE:688136) » Definitions » Financial Strength

Shan Dong Kexing Bioproducts Co (SHSE:688136) Financial Strength : 4 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shan Dong Kexing Bioproducts Co Financial Strength?

Shan Dong Kexing Bioproducts Co has the Financial Strength Rank of 4.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Shan Dong Kexing Bioproducts Co's Interest Coverage for the quarter that ended in Mar. 2024 was 2.71. Shan Dong Kexing Bioproducts Co's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.83. As of today, Shan Dong Kexing Bioproducts Co's Altman Z-Score is 2.04.


Competitive Comparison of Shan Dong Kexing Bioproducts Co's Financial Strength

For the Biotechnology subindustry, Shan Dong Kexing Bioproducts Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shan Dong Kexing Bioproducts Co's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shan Dong Kexing Bioproducts Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where Shan Dong Kexing Bioproducts Co's Financial Strength falls into.



Shan Dong Kexing Bioproducts Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Shan Dong Kexing Bioproducts Co's Interest Expense for the months ended in Mar. 2024 was ¥-10 Mil. Its Operating Income for the months ended in Mar. 2024 was ¥27 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥655 Mil.

Shan Dong Kexing Bioproducts Co's Interest Coverage for the quarter that ended in Mar. 2024 is

Interest Coverage=-1*Operating Income (Q: Mar. 2024 )/Interest Expense (Q: Mar. 2024 )
=-1*27.168/-10.04
=2.71

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Shan Dong Kexing Bioproducts Co's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(537.989 + 655.045) / 1442.656
=0.83

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Shan Dong Kexing Bioproducts Co has a Z-score of 2.04, indicating it is in Grey Zones. This implies that Shan Dong Kexing Bioproducts Co is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 2.04 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shan Dong Kexing Bioproducts Co  (SHSE:688136) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Shan Dong Kexing Bioproducts Co has the Financial Strength Rank of 4.


Shan Dong Kexing Bioproducts Co Financial Strength Related Terms

Thank you for viewing the detailed overview of Shan Dong Kexing Bioproducts Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Shan Dong Kexing Bioproducts Co (SHSE:688136) Business Description

Traded in Other Exchanges
N/A
Address
No. 2666, Chuangye Road, Mingshui Development Zone, Zhangqiu District, Shandong Province, Jinan, CHN, 250200
Shan Dong Kexing Bioproducts Co Ltd formerly Kexing Biopharmaceutical Co Ltd is an innovative biopharmaceutical company. It is engaged in the production and sales of recombinant protein drugs and probiotics. The company use the drugs in the fields of antiviral, hematology, tumor and immunity, and degenerative diseases.
Executives
Wang Xiao Qin Directors, senior managers
Cui Ning Directors, senior managers
Ma Hong Jie senior management
Shao Ke senior management
Deng Xue Qin Director
Zhao Yan Qing Directors, senior managers

Shan Dong Kexing Bioproducts Co (SHSE:688136) Headlines

No Headlines